• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Brian Buntz

VC-backed startup Bionaut Labs intends to use tiny robots for drug delivery

March 3, 2021 By Brian Buntz

Bionaut Labs

Every once in a while, researchers invoke the 1966 film Fantastic Voyage to describe efforts to use nanotechnology to deliver drugs in the body. A submarine crew shrunk to microscopic size work to damage an injured scientist’s brain in the film. Now, the company Bionaut Labs (Los Angeles) has emerged from stealth mode to describe […]

Filed Under: Drug-Device Combinations, Funding Roundup, Oncology Tagged With: Bionaut Labs, Drug delivery

Semaglutide paired with behavioral therapy tripled weight loss in trial

February 24, 2021 By Brian Buntz

Novo Nordisk

The diabetes drug Ozempic (semaglutide) could potentially enhance weight loss in overweight and obese patients without diabetes, according to a study recently published in JAMA and The New England Journal of Medicine. In December, Novo Nordisk (NYSE:NVO) submitted a new drug application to the FDA for a 2.4-mg dose of subcutaneous semaglutide for chronic weight management. Get the full story […]

Filed Under: Diabetes Tagged With: Diabetes, Novo Nordisk, semaglutide

Looking back at two decades of CGM advances

February 10, 2021 By Brian Buntz

FreeStyle Libre 2 from Abbott

Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history. Attempts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose […]

Filed Under: Diabetes, Drug-Device Combinations, Food & Drug Administration (FDA), mHealth (Mobile Health) Tagged With: abbott, DexCom Inc., diabetes management, digital health, Eversense, FDA, Medtronic, mhealth, Senseonics

Why COVID-19 could drive a surge in diabetes 

February 1, 2021 By Brian Buntz

diabetes devices

Diabetes was already an epidemic before the novel coronavirus struck. But some researchers now suspect that COVID-19 can trigger the condition. Approximately 14% of patients with severe COVID-19 develop the disease, according to a meta-analysis recently published in the journal Diabetes, Obesity and Metabolism. To arrive at that thesis, the researchers analyzed eight studies. Half of […]

Filed Under: Diabetes, Featured Tagged With: COVID-19, Diabetes, novel coronavirus

Catalent to acquire Acorda’s manufacturing and packaging operations

January 28, 2021 By Brian Buntz

Catalent

Catalent (NYSE:CTLT) has entered into a definitive agreement to purchase a dry-powder inhaler (DPI) capsule manufacturing and packaging facility from Acorda Therapeutics (NSDQ:ACOR). The acquisition will enable Catalent to establish a center of excellence for spray-dried dispersion for DPI capsule manufacturing. The transaction will also expand Catalent’s existing U.S.-based commercial-scale capabilities in metered-dose inhalers and nasal […]

Filed Under: Drug-Device Combinations, Pharmaceuticals, Respiratory

How CGMs can inspire lifestyle changes

January 27, 2021 By Brian Buntz

G6

As an early adopter of fitness trackers such as the Fitbit, I’ve long appreciated the power of health data. But my recent experience with a continuous glucose monitor (CGM) has done far more to inspire me to look after my health — even as a nondiabetic. I had heard about the potential of such technology […]

Filed Under: Diabetes, Featured Tagged With: blood glucose monitoring, Dexcom, Diabetes, G6

How continuous glucose monitors have transformed the diabetes landscape

January 25, 2021 By Brian Buntz

G6

Continuous glucose monitors (CGMs) are among the most potent diabetes management tools to emerge in recent decades. FDA approved the first professional CGM in 1999, and the technology has evolved swiftly since then. Current models beam data via Bluetooth to smartphones (plus the Apple Watch) and the cloud, enabling patients to explore their blood glucose […]

Filed Under: Diabetes, Featured Tagged With: A1C, blood glucose monitoring, CDC, CGM, continuous glucose monitor, Diabetes, fingerstick, hypoglycemia, smartphone

FDA approves Guerbet’s Optiray imaging bulk package

December 4, 2020 By Brian Buntz

Guerbet

Guerbet (EPA:GBT), which specializes in medical imaging including contrast agents, has received FDA approval for its Optiray imaging bulk package, which can be used to fill sterile disposable syringes for use with CT imaging.  The imaging bulk package is intended to reduce the number of single-dose vials when used with a power injector and contrast […]

Filed Under: Auto-injectors, Imaging Tagged With: Guerbet, imaging bulk package, Optiray, syringes

OncoSec announces positive results in metastatic melanoma case study

December 4, 2020 By Brian Buntz

Oncosec

The International Journal of Surgery Case Reports has published a case study on the use of the humanized antibody Keytruda (pembrolizumab) and tavokinogene telseplasmid (TAVO) from OncoSec (NSDQ:ONCS) for treating metastatic melanoma. The study involved a patient with stage IIB, pT3b melanoma who initially underwent tumor resection but experienced regional recurrence and later disease progression […]

Filed Under: Immunotherapy, Oncology, Surgical Tagged With: electroporation, Keytruda, melanoma, Oncosec, pembrolizumab, TAVO, tavokinogene telseplasmid

Lilly and Ypsomed team up on automated insulin delivery

November 19, 2020 By Brian Buntz

Eli Lilly

Eli Lilly (NYSE:LLY) and Ypsomed (SWX:YPSN) are teaming up to create an automated insulin delivery system. Lilly would commercialize the device, which would incorporate an insulin pump from Ypsomed. Burgdorf, Switzerland-based Ypsomed launched its Mylife YpsoPump in Europe in 2016. Now available in 21 countries, the pump includes a touch screen. Lilly plans on commercializing […]

Filed Under: Diabetes, Drug-Device Combinations Tagged With: Eli Lilly & Co., Novo Nordisk, Ypsomed, YpsoPump

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS